Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Choroideremia, CHM (Choroideremia) Gene Mutations
- Main trialPhase 1/2
- “This clinical study evaluates the safety and tolerability of AAV2-hCHM in participants with Choroideremia gene mutations.”In the company’s words, NCT02341807 on ClinicalTrials.gov
Other drugs for Choroideremia
- 4D-1104D Molecular Therapeutics · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 12 Oct 2022 | Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026